Maternal Digital Biobanks for Precision Pregnancy Monitoring

Abstract

Digital biobanks have emerged as transformative platforms in maternal-fetal medicine, integrating multi-dimensional clinical, genetic, and digital phenotypic data to enable precision pregnancy monitoring. This review examines the current landscape, including epidemiology, pathophysiology, risk stratification, diagnostic modalities, and management strategies, with a focus on the clinical utility and future potential of maternal digital biobanks. The article synthesizes recent evidence and guideline-based practices, providing actionable insights for healthcare professionals seeking to leverage biobank-driven precision approaches in obstetric care.

Introduction

Maternal digital biobanks are structured repositories collecting extensive digital, clinical, genomic, and biospecimen data from pregnant individuals. These platforms support high-resolution, longitudinal tracking of physiological and pathological changes during pregnancy. By harmonizing real-world and molecular datasets, digital biobanks facilitate the identification of novel biomarkers, disease trajectories, and individualized risk profiles, thereby promoting precision medicine in obstetric care. The integration of electronic health records (EHRs), wearable sensor data, and omics profiles underpins a paradigm shift from generalized to patient-tailored monitoring, diagnosis, and intervention strategies.

Epidemiology / Disease Burden

Pregnancy complications such as preeclampsia, gestational diabetes mellitus (GDM), preterm birth, and fetal growth restriction contribute substantially to maternal and perinatal morbidity and mortality globally. The World Health Organization estimates that approximately 810 women die every day from preventable pregnancy or childbirth-related complications, many of which could be mitigated with early and precise monitoring. Traditional risk assessment methods, often based on static clinical variables, fall short in capturing the dynamic pathophysiology of pregnancy. Digital biobanks address this gap by enabling large-scale, real-world data aggregation and continuous risk stratification, offering the potential to reduce adverse outcomes through proactive, data-driven care.

Pathophysiology

Pregnancy involves complex physiological adaptations, including immunological tolerance, angiogenesis, metabolic changes, and hormonal shifts. Pathological deviations from these processes underlie common complications. For example, impaired spiral artery remodeling contributes to preeclampsia, while dysregulated placental insulin signaling is central to GDM. Digital biobanks allow for the systematic capture of proteomic, metabolomic, and transcriptomic signatures alongside clinical phenotypes, facilitating the elucidation of mechanistic pathways. Integrating digital phenotyping (e.g., continuous blood pressure, glucose monitoring) with molecular data enhances our understanding of the temporal evolution and heterogeneity of disease mechanisms in pregnancy.

Risk Factors

Key risk factors for adverse pregnancy outcomes include advanced maternal age, obesity, pre-existing hypertension or diabetes, genetic predispositions, and socioeconomic determinants. Traditional risk models often underperform in diverse populations due to limited data granularity. Digital biobanks enable the inclusion of underrepresented groups and social determinants of health, improving both the sensitivity and specificity of risk prediction algorithms. Moreover, the ongoing collection of behavioral and environmental data (e.g., diet, physical activity, air quality) provides a more holistic assessment of modifiable and non-modifiable risks.

Clinical Features

Clinically, early recognition of abnormal patterns in maternal vital signs, biochemical markers, and fetal growth trajectories is critical for timely intervention. Digital biobanks make it feasible to monitor subtle deviations in real time, capturing prodromal changes that often precede clinical manifestations of complications like preeclampsia or preterm labor. For instance, remote monitoring of blood pressure, weight, and physical activity using wearables can alert clinicians to emerging hypertensive disorders before overt symptoms arise. The continuous, multidimensional data stream enhances the detection of at-risk pregnancies beyond intermittent in-clinic assessments.

Diagnosis

Traditional diagnosis of pregnancy complications relies on periodic assessments and laboratory investigations, which may miss transient or early abnormalities. Digital biobanks, by integrating continuous biosensor data, advanced imaging, and molecular diagnostics, enable earlier and more accurate detection of pathology. Machine learning algorithms trained on biobank data can identify complex patterns predictive of disease onset, facilitating pre-symptomatic diagnosis. Furthermore, the linkage of maternal and fetal datasets allows for comprehensive maternal-fetal health surveillance, supporting precision diagnostics at both individual and population levels.

Treatment & Management

Personalized management strategies informed by digital biobank data hold promise for optimizing maternal and fetal outcomes. Data-driven risk stratification enables targeted surveillance and early intervention for high-risk pregnancies. For example, continuous glucose monitoring data can guide individualized therapy in GDM, while digital phenotyping supports tailored antihypertensive protocols in preeclampsia. Biobank-enabled telemedicine platforms further enhance access to specialist care, particularly in underserved regions. Integration with clinical decision support systems (CDSS) ensures that real-time data analytics inform evidence-based, patient-specific care pathways.

Recent Advances / Emerging Therapies

Recent advances in digital biobanking include the adoption of federated learning, which allows multi-institutional data sharing without compromising patient privacy. Artificial intelligence (AI)-driven analytics are increasingly applied to identify novel biomarkers, predict adverse outcomes, and personalize interventions. Emerging research focuses on multi-omics integration, digital twin modeling, and the use of digital endpoints for clinical trials in pregnancy. The implementation of blockchain technology enhances data security and patient consent management. These innovations are rapidly expanding the scope and applicability of digital biobanks in maternal-fetal medicine.

Guideline Recommendations

Leading organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the International Federation of Gynecology and Obstetrics (FIGO) endorse the integration of digital health solutions into routine prenatal care. Recent guidelines recommend leveraging digital biobanks for risk stratification, early detection of complications, and continuous patient engagement, while emphasizing the need for robust data governance and equity in access. Clinicians are encouraged to adopt evidence-based digital tools, participate in biobank-driven research, and contribute to the development of interoperable data standards to maximize the clinical utility of these platforms.

Conclusion

Maternal digital biobanks represent a pivotal advancement in precision pregnancy monitoring, offering unprecedented opportunities for early detection, risk stratification, and individualized care. Their integration into clinical practice is poised to transform maternal-fetal medicine, reducing the burden of pregnancy complications and improving outcomes for mothers and infants. Ongoing collaboration among clinicians, researchers, and policymakers is essential to address ethical, legal, and social challenges, ensuring that the benefits of digital biobanking are realized equitably on a global scale.